- Home
- IBG vs CMND Comparison
IBG vs CMND Comparison
Compare IBG & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | CMND |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Australia | Canada |
| Employees | 9 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBG | CMND |
|---|---|---|
| Price | $3.75 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 130.7K | 108.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.07 |
| 52 Week High | $6.50 | $3.25 |
Technical Indicators
Market Signals| Indicator | IBG | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 37.40 |
| Support Level | $3.61 | $0.98 |
| Resistance Level | $5.12 | $1.27 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 15.62 | 63.64 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.